Tharimmune, Inc.

THAR

US4327053090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 11:00:00 03/07/2024 pm IST			5-day change	1st Jan Change
3.32 ^USD	+0.30%		+7.10%	-56.52%

28/06	Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group	CI
20/06	Tharimmune Prices $2.1 Million Private Placement of Common Shares, Warrants	MT

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

June 28, 2024

On June 28, 2024, Tharimmune, Inc., closed the transaction. The transaction included participation from 5 investors.

Latest news about Tharimmune, Inc.

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group	28/06	CI
Tharimmune Prices $2.1 Million Private Placement of Common Shares, Warrants	20/06	MT
Tharimmune, Inc. announced that it expects to receive $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group and other investors	18/06	CI
Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis	17/06	CI
Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis	10/06	CI
Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	25/05	CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	25/05	CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	25/05	CI
Tharimmune to Implement 1-for-15 Reverse Stock Split	22/05	MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	23/04	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	20/02	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	05/02	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	29/01	CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	11/12	MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	11/12	CI
Sector Update: Health Care Stocks Retreat in Late Afternoon	29/11	MT
Top Midday Decliners	29/11	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	28/11	MT
Top Premarket Decliners	28/11	MT
Tharimmune Prices $10 Million Public Share Offering	28/11	MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	27/11	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	18/11	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	18/11	MT

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.32 USD

Average target price

75 USD

Spread / Average Target

+2,159.03%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-56.52%	26.02L
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+17.55%	2.62TCr
BIONTECH SE	-24.33%	1.9TCr
GENMAB A/S	-19.14%	1.57TCr
BEIGENE, LTD.	-17.95%	1.52TCr
WUXI APPTEC CO., LTD.	-46.81%	1.47TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.38TCr

Bio Therapeutic Drugs

Tharimmune, Inc.

Equities

THAR

US4327053090

Biotechnology & Medical Research

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Latest news about Tharimmune, Inc.

Chart Tharimmune, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs